HPP AMG :@0.171081:0.940294:0.280299:0.940294:0.280299:0.918072:0.171081:0.918072:0.016043:0.013639:0.013639:0.005905:0.014867:0.022549:0.016672:0.005905
 Infections In Immunocompromised Patients  :@0.765083:0.940294:1.247948:0.940294:1.247948:0.918072:0.765083:0.918072:0.005938:0.006584:0.013613:0.007708:0.013012:0.011314:0.008884:0.006010:0.013587:0.013717:0.010033:0.005905:0.006584:0.013639:0.005905:0.006584:0.020772:0.020772:0.013717:0.013587:0.013665:0.011261:0.013665:0.020772:0.014214:0.008910:0.013665:0.020772:0.006010:0.010033:0.013012:0.013717:0.005905:0.013665:0.012515:0.008831:0.006010:0.013012:0.013639:0.008884:0.010086:0.006853:0.005905
 :@1.829525:0.940294:1.835430:0.940294:1.835430:0.918072:1.829525:0.918072:0.005905
40 :@1.802803:0.940294:1.835430:0.940294:1.835430:0.918072:1.802803:0.918072:0.013064:0.013658:0.005905
13. :@0.213836:0.144185:0.261534:0.144185:0.261534:0.121697:0.213836:0.121697:0.016033:0.016033:0.007708:0.007924
Infections following haematopoietic stem cell transplant:@0.256580:0.144185:1.016257:0.144185:1.016257:0.121697:0.256580:0.121697:0.007724:0.017216:0.009492:0.016019:0.016019:0.009492:0.007724:0.017216:0.017216:0.016019:0.007724:0.009492:0.017786:0.007724:0.007724:0.017216:0.023145:0.007724:0.017216:0.017216:0.007724:0.017216:0.016019:0.016019:0.025511:0.016019:0.009492:0.017216:0.017216:0.017216:0.007724:0.016019:0.009492:0.007724:0.016019:0.007724:0.016019:0.009492:0.016019:0.025511:0.007724:0.016019:0.016019:0.008295:0.007724:0.007724:0.009492:0.011259:0.016019:0.017216:0.016019:0.017216:0.007724:0.016019:0.017216:0.009492
 are generally similar to that in the solid organ transplant setting. :@1.016936:0.144185:1.833268:0.144185:1.833268:0.121697:1.016936:0.121697:0.007720:0.016019:0.009492:0.016019:0.007724:0.016019:0.016019:0.016019:0.016019:0.009492:0.016019:0.005929:0.006499:0.013653:0.007724:0.014822:0.005929:0.023743:0.006499:0.005929:0.016019:0.009492:0.007724:0.007724:0.016019:0.008295:0.007724:0.016019:0.016019:0.007724:0.007724:0.005929:0.016019:0.008295:0.007724:0.016019:0.016019:0.007724:0.014252:0.016019:0.005929:0.005929:0.016019:0.007724:0.016019:0.009492:0.016019:0.016019:0.016019:0.007724:0.007724:0.009492:0.016019:0.016019:0.014252:0.016019:0.005929:0.016019:0.016019:0.007724:0.007724:0.014252:0.016019:0.007724:0.007724:0.005929:0.016019:0.016019:0.009116:0.007924
 :@0.256580:0.167345:0.264504:0.167345:0.264504:0.144857:0.256580:0.144857:0.007924
a.  In  addition  to  the  usual  bacterial,  fungal  infections  and  viral  infections  especially :@0.299335:0.190454:1.417230:0.190454:1.417230:0.167966:0.299335:0.167966:0.016033:0.007791:0.007924:0.011078:0.007126:0.016589:0.007924:0.005701:0.016019:0.016019:0.016019:0.005929:0.007724:0.005929:0.016019:0.016019:0.007924:0.006299:0.007724:0.016019:0.007924:0.005701:0.007724:0.016019:0.016019:0.007924:0.005701:0.016019:0.014252:0.016019:0.016019:0.005929:0.007924:0.005701:0.016019:0.016019:0.014252:0.007724:0.016019:0.010062:0.005929:0.016019:0.005929:0.008295:0.007924:0.005701:0.007724:0.016019:0.016019:0.016019:0.016019:0.005929:0.007924:0.006299:0.005929:0.016019:0.007724:0.016019:0.014822:0.007724:0.005929:0.016019:0.016019:0.014252:0.007924:0.005701:0.016019:0.016019:0.016019:0.007924:0.005701:0.014822:0.005929:0.009492:0.016019:0.005929:0.007924:0.006299:0.005929:0.016019:0.007724:0.016019:0.014252:0.008295:0.005929:0.016019:0.016019:0.014252:0.007924:0.005701:0.016019:0.014252:0.016019:0.016019:0.014252:0.005929:0.016019:0.005929:0.006499:0.014252:0.007924
CMV:@1.424394:0.190413:1.487900:0.190413:1.487900:0.167966:1.424394:0.167966:0.020751:0.023743:0.019012
  reactivation  and  parasitic :@1.487933:0.190454:1.837017:0.190454:1.837017:0.167966:1.487933:0.167966:0.007924:0.005758:0.009492:0.016019:0.016019:0.014252:0.007724:0.005929:0.014822:0.016019:0.007724:0.005929:0.016019:0.016019:0.007924:0.005701:0.016019:0.016019:0.016019:0.007924:0.005701:0.016019:0.016019:0.009492:0.016019:0.014252:0.005929:0.007724:0.005929:0.014822:0.007924
infections e.g. :@0.342162:0.213983:0.525753:0.213983:0.525753:0.191496:0.342162:0.191496:0.005929:0.016019:0.007724:0.016019:0.014252:0.007724:0.005929:0.016019:0.016019:0.014252:0.007724:0.016019:0.007724:0.016019:0.008295:0.007924
Pneumocystis jiroveci:@0.525724:0.213943:0.799672:0.213943:0.799672:0.191496:0.525724:0.191496:0.019012:0.015990:0.016019:0.016019:0.023145:0.016019:0.014252:0.014252:0.014252:0.007724:0.005929:0.014822:0.007724:0.006499:0.005929:0.009492:0.016019:0.014252:0.016019:0.014252:0.006328
 (PJP) and toxoplasma infection can occur.  :@0.799525:0.213983:1.358090:0.213983:1.358090:0.191496:0.799525:0.191496:0.007720:0.009501:0.019002:0.014252:0.019002:0.010062:0.007724:0.016019:0.016019:0.016019:0.007862:0.007720:0.016019:0.014252:0.016019:0.016019:0.005929:0.016019:0.014252:0.023743:0.016019:0.007724:0.005929:0.016019:0.007724:0.016019:0.014252:0.007724:0.005929:0.016019:0.016219:0.007720:0.014252:0.016019:0.016019:0.007724:0.016019:0.014252:0.014252:0.016019:0.009492:0.007724:0.008418:0.007924
 :@0.342162:0.237092:0.350086:0.237092:0.350086:0.214605:0.342162:0.214605:0.007924
b.  It is recommended that prophylactic use of ganciclovir or pre-emptive monitoring for :@0.299335:0.260252:1.390470:0.260252:1.390470:0.237765:0.299335:0.237765:0.016033:0.007791:0.007924:0.011078:0.007724:0.007724:0.007126:0.005929:0.014822:0.006527:0.009492:0.016019:0.014252:0.016019:0.023743:0.023743:0.016019:0.016019:0.016019:0.015449:0.016019:0.006527:0.007724:0.016019:0.016019:0.007724:0.006527:0.016019:0.009492:0.016019:0.016019:0.016019:0.013653:0.005929:0.016019:0.014252:0.008295:0.005929:0.014252:0.006527:0.016019:0.014252:0.016019:0.006527:0.016019:0.008295:0.007007:0.016033:0.016019:0.016019:0.014252:0.006499:0.014252:0.005929:0.016019:0.014822:0.005929:0.009492:0.006527:0.016019:0.009492:0.006527:0.016019:0.009492:0.016290:0.009501:0.016019:0.023743:0.016019:0.007724:0.005929:0.014822:0.016019:0.006527:0.023743:0.016019:0.016019:0.005929:0.007724:0.016019:0.009492:0.005957:0.016019:0.016019:0.006527:0.007724:0.016019:0.009492:0.007924
CMV:@1.389382:0.260212:1.452888:0.260212:1.452888:0.237765:1.389382:0.237765:0.021349:0.023145:0.019012
 reactivation should be carried :@1.452898:0.260252:1.837040:0.260252:1.837040:0.237765:1.452898:0.237765:0.006556:0.009492:0.016019:0.016019:0.014252:0.008295:0.005929:0.014822:0.016019:0.007724:0.005929:0.016019:0.016019:0.006527:0.014252:0.016019:0.016019:0.016019:0.005929:0.016019:0.006527:0.016019:0.016019:0.006527:0.014252:0.016019:0.009492:0.009492:0.005957:0.016019:0.016019:0.007924
out during the first 100 days.  :@0.342162:0.283361:0.717781:0.283361:0.717781:0.260874:0.342162:0.260874:0.016019:0.016019:0.007724:0.007724:0.016019:0.016019:0.009492:0.005957:0.016019:0.016019:0.007724:0.007724:0.016019:0.016019:0.007724:0.007724:0.005929:0.009492:0.014252:0.008295:0.007724:0.016019:0.016019:0.016019:0.007724:0.016019:0.016019:0.013653:0.014252:0.007724:0.008608:0.007924
 :@0.171081:0.306471:0.179005:0.306471:0.179005:0.283983:0.171081:0.283983:0.007924
c.  Trimethoprim/sulfamethoxazole (80/400mg) once daily is extremely effective in the prevention of PJP or toxoplasmosis.  :@0.299335:0.330000:1.845739:0.330000:1.845739:0.307513:0.299335:0.307513:0.014252:0.007791:0.007924:0.012860:0.016618:0.010062:0.005929:0.023743:0.016019:0.007724:0.016019:0.016019:0.016019:0.009492:0.005957:0.023743:0.007905:0.014252:0.016019:0.006499:0.007724:0.016019:0.023743:0.016019:0.007724:0.016019:0.016019:0.014252:0.016019:0.014252:0.016019:0.005929:0.015848:0.008689:0.008893:0.016019:0.016019:0.007724:0.016019:0.016019:0.016019:0.023145:0.016019:0.009492:0.006651:0.016019:0.016019:0.013653:0.016019:0.006527:0.016019:0.016019:0.005929:0.006499:0.013653:0.007126:0.005929:0.014252:0.006527:0.016019:0.014252:0.007724:0.009492:0.016019:0.023743:0.016019:0.006499:0.013653:0.006527:0.016019:0.008295:0.007724:0.016019:0.014252:0.007724:0.005929:0.014822:0.016019:0.006527:0.005929:0.016019:0.006527:0.007724:0.016019:0.016019:0.007107:0.016019:0.009492:0.016019:0.014822:0.016019:0.016019:0.007724:0.005929:0.016019:0.016019:0.006527:0.016019:0.007724:0.005929:0.019197:0.014252:0.019002:0.006532:0.016019:0.009492:0.006527:0.007724:0.016019:0.014252:0.016019:0.016019:0.005929:0.016019:0.014252:0.023743:0.016019:0.014252:0.005929:0.014252:0.008295:0.008504:0.007924
 :@0.740143:0.330706:0.749387:0.330706:0.749387:0.304471:0.740143:0.304471:0.009245
 :@0.256580:0.353529:0.264504:0.353529:0.264504:0.331042:0.256580:0.331042:0.007924
a.  It is recommended that these measures be continued in patients with active graft-vs-host disease and in those remaining :@0.299335:0.377933:1.837002:0.377933:1.837002:0.355445:0.299335:0.355445:0.016033:0.007791:0.007924:0.011078:0.007724:0.007724:0.005929:0.005929:0.014822:0.005929:0.009492:0.016019:0.014252:0.016019:0.023743:0.023743:0.016019:0.016019:0.016019:0.015449:0.016019:0.005929:0.007724:0.016019:0.016019:0.007724:0.005929:0.007724:0.016019:0.016019:0.014252:0.016019:0.005929:0.023743:0.016019:0.016019:0.013653:0.016019:0.009492:0.016019:0.014252:0.005929:0.015449:0.016019:0.005929:0.014252:0.016019:0.016019:0.007724:0.005929:0.016019:0.016019:0.016019:0.016019:0.005929:0.005929:0.016019:0.005929:0.016019:0.016019:0.007724:0.005929:0.016019:0.016019:0.007724:0.014252:0.005929:0.020181:0.005929:0.007724:0.016019:0.005929:0.016019:0.014252:0.008295:0.005929:0.014822:0.016019:0.005929:0.016019:0.009492:0.016019:0.007724:0.008703:0.009501:0.014846:0.014276:0.008884:0.016019:0.016019:0.014252:0.007724:0.005929:0.016019:0.005929:0.014252:0.016019:0.016019:0.014252:0.015449:0.005929:0.016019:0.016019:0.016019:0.005929:0.005929:0.016019:0.005929:0.007724:0.016019:0.016019:0.014252:0.016019:0.005929:0.009492:0.016019:0.023743:0.016019:0.005929:0.016019:0.005929:0.016019:0.015449:0.007924
on high dose immunosuppressive agents. :@0.342162:0.401462:0.876333:0.401462:0.876333:0.378975:0.342162:0.378975:0.016019:0.016019:0.007724:0.016019:0.005929:0.016019:0.016019:0.007724:0.016019:0.016019:0.014252:0.016019:0.007724:0.005929:0.023743:0.023743:0.016019:0.016019:0.016019:0.014252:0.015449:0.016019:0.016019:0.009492:0.016019:0.014252:0.014252:0.005330:0.014822:0.016019:0.007724:0.016019:0.016019:0.015449:0.016019:0.007724:0.014252:0.008138:0.007924
 :@0.171081:0.425412:0.179005:0.425412:0.179005:0.402924:0.171081:0.402924:0.007924
14. Attention must be paid to: :@0.213836:0.451882:0.587686:0.451882:0.587686:0.429395:0.213836:0.429395:0.016033:0.016033:0.007708:0.002969:0.019012:0.007724:0.007724:0.016019:0.016019:0.007724:0.005929:0.016019:0.016019:0.007724:0.023743:0.016019:0.014252:0.007724:0.007724:0.016019:0.016019:0.007724:0.016019:0.016019:0.005929:0.016019:0.007724:0.007724:0.016019:0.008589:0.007924
 :@0.171081:0.478387:0.179005:0.478387:0.179005:0.455899:0.171081:0.455899:0.007924
a.  Strict isolation measures with good personal hygiene and diet. :@0.299335:0.501496:1.132983:0.501496:1.132983:0.479008:0.299335:0.479008:0.016033:0.007791:0.007924:0.011078:0.019012:0.007724:0.009492:0.005957:0.014252:0.008295:0.007724:0.005929:0.014252:0.016589:0.005929:0.016019:0.007724:0.005929:0.016019:0.016019:0.007886:0.023743:0.016019:0.016019:0.014252:0.016019:0.009492:0.016019:0.014328:0.008290:0.020181:0.005929:0.007724:0.016019:0.007724:0.016019:0.016019:0.016019:0.016019:0.007724:0.016019:0.016019:0.009492:0.014252:0.016019:0.015449:0.016019:0.005929:0.007724:0.016019:0.014252:0.016019:0.005929:0.016019:0.016019:0.016019:0.007724:0.016019:0.016019:0.016019:0.007724:0.016019:0.005929:0.016019:0.007724:0.008195:0.007924
b.  Modification of antibiotic regimen if deterioration of clinical status  :@0.299335:0.524605:1.170988:0.524605:1.170988:0.502118:0.299335:0.502118:0.016033:0.007791:0.007924:0.011078:0.023145:0.016019:0.016019:0.005929:0.008295:0.005929:0.014252:0.016019:0.008295:0.005929:0.016019:0.016019:0.007724:0.016019:0.007724:0.007724:0.016019:0.016019:0.007724:0.005929:0.016589:0.005929:0.016019:0.007724:0.005929:0.014822:0.007724:0.009492:0.016019:0.016019:0.005929:0.023743:0.016019:0.016019:0.007724:0.005929:0.008295:0.007724:0.016019:0.016019:0.007724:0.016019:0.009492:0.005957:0.016019:0.009492:0.016019:0.007724:0.005929:0.016019:0.016589:0.007724:0.016019:0.007724:0.007724:0.014252:0.006499:0.005929:0.016019:0.005929:0.014252:0.016589:0.005929:0.007724:0.014252:0.007724:0.016019:0.007724:0.016019:0.014252:0.009178:0.007924
c.  The antibiotics are generally kept for a minimal duration of 5 to 7 days or stopped if afebrile for 3 days in patients with :@0.299335:0.547714:1.835634:0.547714:1.835634:0.525227:0.299335:0.525227:0.014252:0.007791:0.007924:0.012860:0.016618:0.016019:0.016019:0.008295:0.016019:0.016019:0.007724:0.005929:0.016589:0.005929:0.016019:0.007724:0.005929:0.014252:0.014822:0.008295:0.016019:0.009492:0.016019:0.008295:0.016019:0.016019:0.016019:0.016019:0.009492:0.016019:0.005929:0.005929:0.013653:0.008295:0.014252:0.016019:0.016019:0.007724:0.008295:0.007724:0.016019:0.009492:0.008295:0.016019:0.008295:0.024314:0.005929:0.016019:0.005929:0.023743:0.016618:0.005929:0.008893:0.016019:0.016019:0.009492:0.016019:0.007724:0.005929:0.016019:0.016019:0.008295:0.016019:0.007724:0.008295:0.016019:0.008295:0.007724:0.016019:0.008295:0.016019:0.008295:0.016019:0.016019:0.013653:0.014252:0.008295:0.016019:0.009492:0.008295:0.014252:0.007724:0.016019:0.016019:0.016019:0.016019:0.016019:0.008295:0.005929:0.007724:0.008295:0.016019:0.007724:0.016019:0.016019:0.009492:0.005957:0.005929:0.016019:0.008893:0.007724:0.016019:0.009492:0.008893:0.016019:0.008295:0.016019:0.016019:0.013653:0.014252:0.008295:0.005929:0.016019:0.008295:0.016019:0.016019:0.007724:0.005929:0.016019:0.016019:0.007724:0.014252:0.008893:0.020181:0.006499:0.007724:0.016019:0.007924
improving neutrophil counts :@0.342162:0.571294:0.698732:0.571294:0.698732:0.548807:0.342162:0.548807:0.005929:0.023743:0.016019:0.009492:0.016019:0.014822:0.005929:0.016019:0.016019:0.007724:0.016019:0.016019:0.016019:0.007948:0.009492:0.015449:0.016019:0.016019:0.005929:0.005929:0.007724:0.014252:0.016019:0.016019:0.016019:0.007724:0.014333:0.007924
d.  Regular culture and surveillance :@0.299335:0.594403:0.757568:0.594403:0.757568:0.571916:0.299335:0.571916:0.016033:0.007791:0.007924:0.011078:0.020751:0.016019:0.016019:0.016019:0.005929:0.016019:0.009492:0.007724:0.014252:0.016019:0.005929:0.007724:0.016019:0.009492:0.016019:0.007724:0.016019:0.016019:0.016019:0.007724:0.014252:0.016019:0.008893:0.014822:0.016019:0.005929:0.005929:0.005929:0.016019:0.016019:0.014252:0.016470:0.007924
e.  HANDWASHING and strict aseptic technique :@0.299335:0.617513:0.920347:0.617513:0.920347:0.595025:0.299335:0.595025:0.016033:0.007791:0.007924:0.011078:0.020751:0.019012:0.020751:0.019582:0.027876:0.019012:0.019012:0.020751:0.007126:0.020751:0.021976:0.007724:0.016019:0.016019:0.016019:0.007724:0.014252:0.007724:0.009492:0.005957:0.014252:0.008295:0.007724:0.016019:0.014252:0.016019:0.016019:0.007724:0.005929:0.014252:0.008295:0.007724:0.016019:0.014252:0.016019:0.016019:0.005929:0.016019:0.016019:0.015952:0.007924
f.  Venous cannula must be inspected daily for signs of phlebitis and changed every 72h or when necessary. Central :@0.299335:0.640622:1.835720:0.640622:1.835720:0.618134:0.299335:0.618134:0.007720:0.008385:0.007924:0.018798:0.019012:0.015990:0.016019:0.016019:0.016019:0.014252:0.011259:0.013653:0.016019:0.016019:0.015449:0.016019:0.005929:0.016019:0.011259:0.023743:0.016019:0.014252:0.007724:0.011259:0.016019:0.016019:0.011259:0.005929:0.016019:0.014252:0.016019:0.016019:0.014252:0.007724:0.015449:0.016019:0.011259:0.016019:0.016019:0.005929:0.005929:0.013653:0.011259:0.007724:0.016019:0.009492:0.011259:0.014822:0.006499:0.016019:0.016019:0.014252:0.011259:0.016019:0.007724:0.011259:0.016019:0.016019:0.005929:0.016019:0.016019:0.005929:0.007724:0.005929:0.014252:0.011259:0.016019:0.016019:0.016019:0.011259:0.014252:0.016019:0.015449:0.016019:0.016019:0.015449:0.016019:0.011259:0.015449:0.014822:0.016019:0.009492:0.013653:0.011259:0.016019:0.016019:0.016019:0.010660:0.016019:0.009492:0.011259:0.019582:0.016019:0.016019:0.016019:0.011259:0.016019:0.016019:0.013653:0.016019:0.014252:0.014252:0.016019:0.009492:0.013653:0.007724:0.011259:0.020751:0.016019:0.016019:0.007724:0.009492:0.016019:0.005929:0.007924
devices are to be removed if there is clinical deterioration in spite of appropriate antibiotics for 48-72h :@0.342162:0.663782:1.624195:0.663782:1.624195:0.641294:0.342162:0.641294:0.016019:0.015449:0.014822:0.005929:0.014252:0.016019:0.014252:0.007724:0.016019:0.009492:0.016019:0.007724:0.007724:0.016019:0.007724:0.016019:0.016019:0.007724:0.009492:0.016019:0.023743:0.015449:0.014822:0.016019:0.016019:0.007724:0.005929:0.007724:0.007724:0.007724:0.016019:0.016019:0.009492:0.016019:0.007724:0.005929:0.014252:0.007724:0.014822:0.005929:0.005929:0.016589:0.005929:0.014252:0.016019:0.005929:0.007724:0.016019:0.016019:0.008295:0.016019:0.009492:0.005957:0.016019:0.009492:0.016019:0.008337:0.005929:0.016019:0.016019:0.007724:0.005929:0.016019:0.007724:0.014252:0.016589:0.005929:0.007724:0.016019:0.007724:0.016019:0.007724:0.007724:0.016019:0.016019:0.016019:0.009492:0.016019:0.016019:0.009492:0.005957:0.016019:0.007724:0.016019:0.007724:0.016019:0.016019:0.007724:0.005929:0.016019:0.005929:0.016019:0.008295:0.005929:0.014252:0.014252:0.008295:0.007724:0.016019:0.009492:0.007724:0.016019:0.016546:0.009501:0.016033:0.016033:0.015439:0.007924
 :@0.171081:0.683664:0.177684:0.683664:0.177684:0.664924:0.171081:0.664924:0.006603
References: :@0.187708:0.702941:0.322637:0.702941:0.322637:0.684235:0.187708:0.684235:0.017197:0.013064:0.006603:0.012993:0.007720:0.013064:0.013064:0.012447:0.013064:0.011876:0.007233:0.006603
 :@0.187708:0.722689:0.194311:0.722689:0.194311:0.703983:0.187708:0.703983:0.006603
1.   Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors     to prevent adverse effects in the treatment of malignant :@0.213836:0.742034:1.835368:0.742034:1.835368:0.723328:0.213836:0.723328:0.013064:0.006532:0.006603:0.016544:0.006532:0.016010:0.013064:0.013064:0.005273:0.005392:0.013064:0.011876:0.007102:0.011876:0.006532:0.007102:0.017197:0.013064:0.007720:0.013064:0.011876:0.006532:0.007102:0.017197:0.006603:0.007031:0.017791:0.013064:0.005273:0.011924:0.013064:0.007720:0.007102:0.019596:0.007102:0.007102:0.016010:0.011876:0.013064:0.017197:0.013064:0.008290:0.011283:0.013064:0.008290:0.007102:0.018409:0.006603:0.007031:0.016010:0.013064:0.013064:0.013634:0.007720:0.006603:0.007031:0.016010:0.006603:0.007625:0.018409:0.007720:0.013064:0.013064:0.013064:0.005273:0.013705:0.013064:0.013064:0.005273:0.013135:0.011876:0.005321:0.012755:0.007720:0.011876:0.006532:0.005273:0.020238:0.013064:0.005273:0.013135:0.006603:0.005273:0.013064:0.013064:0.007102:0.007102:0.013064:0.011876:0.006532:0.013064:0.007720:0.011876:0.007696:0.007102:0.007102:0.007102:0.007102:0.006603:0.012993:0.007102:0.013634:0.007720:0.013064:0.011876:0.013064:0.013064:0.007102:0.007102:0.013064:0.013064:0.011876:0.013634:0.007720:0.011876:0.013064:0.007696:0.013064:0.006603:0.006461:0.013064:0.011876:0.006532:0.011876:0.007102:0.005273:0.013135:0.007102:0.006603:0.013563:0.013064:0.007102:0.006603:0.007648:0.013634:0.013064:0.006603:0.019525:0.013634:0.013064:0.006603:0.007031:0.013064:0.006603:0.007031:0.020166:0.013064:0.005273:0.005392:0.013064:0.013064:0.013064:0.013634:0.006603:0.006603
lymphoma. Cochrane Database of Systematic Reviews 2008, Issue 4. :@0.256580:0.761395:0.998599:0.761395:0.998599:0.742689:0.256580:0.742689:0.005273:0.011924:0.019596:0.013064:0.013064:0.013064:0.020166:0.013064:0.006603:0.006580:0.017197:0.013064:0.011876:0.013064:0.008290:0.013064:0.013064:0.013064:0.006603:0.017150:0.013634:0.006603:0.012993:0.013064:0.013064:0.012447:0.013064:0.006603:0.012993:0.006603:0.006461:0.016010:0.011876:0.011876:0.006532:0.013064:0.020166:0.013064:0.006603:0.005273:0.011876:0.006532:0.017197:0.013064:0.011876:0.005321:0.013634:0.016627:0.011876:0.006865:0.013634:0.013064:0.013064:0.013064:0.006603:0.007031:0.005938:0.011876:0.011876:0.013634:0.013064:0.006603:0.012993:0.007268:0.006603
2.  Alison GF, Eirc JB, Kent A S et al. IDSA guideline : Clinical Practice guideline for the Use of Antimicrobial Agents in Neutropenic Patients with cancer :@0.213836:0.780723:1.834941:0.780723:1.834941:0.762017:0.213836:0.762017:0.013064:0.006532:0.006603:0.016544:0.016010:0.005273:0.005392:0.011876:0.013064:0.013064:0.007102:0.018409:0.014252:0.006603:0.007031:0.016010:0.005273:0.007791:0.011876:0.007102:0.011876:0.016010:0.006603:0.007031:0.016010:0.013064:0.013064:0.006603:0.007031:0.016010:0.006603:0.015938:0.007102:0.013064:0.006603:0.007031:0.013064:0.005273:0.006603:0.007102:0.005938:0.017197:0.016010:0.016010:0.007672:0.013064:0.013064:0.005273:0.013135:0.013064:0.005273:0.005392:0.013064:0.013064:0.007102:0.006603:0.007031:0.017197:0.005273:0.005392:0.013064:0.005273:0.011924:0.013064:0.005273:0.007173:0.016010:0.007720:0.013064:0.011876:0.006532:0.005273:0.011924:0.013064:0.007102:0.013064:0.013064:0.005273:0.013135:0.013064:0.005273:0.005392:0.013064:0.013064:0.007102:0.006603:0.013563:0.007720:0.007102:0.006603:0.012993:0.013064:0.007102:0.017197:0.011876:0.013064:0.007102:0.013064:0.006603:0.007031:0.016010:0.013064:0.006603:0.005273:0.019596:0.005273:0.011924:0.007720:0.013634:0.013064:0.005273:0.013135:0.005273:0.007173:0.016010:0.013064:0.013064:0.013064:0.006603:0.011805:0.007102:0.005914:0.013064:0.007102:0.017197:0.013064:0.013064:0.006603:0.007648:0.013064:0.013634:0.013064:0.013064:0.005273:0.011924:0.007102:0.016010:0.013064:0.006603:0.005273:0.013064:0.013064:0.006603:0.011805:0.007696:0.016627:0.005273:0.006603:0.013064:0.007102:0.011876:0.013064:0.013064:0.011876:0.013634:0.007720:0.006603
:2010 update by the Infectious Diseases Society of America . CID 2011; 52: 56-93. :@0.256580:0.800050:1.131069:0.800050:1.131069:0.781345:0.256580:0.781345:0.006603:0.012993:0.013064:0.013064:0.013064:0.006603:0.013563:0.013064:0.013064:0.013064:0.007102:0.013064:0.006603:0.012993:0.011876:0.006532:0.006603:0.013563:0.013064:0.007102:0.005938:0.013064:0.006603:0.012993:0.012447:0.006603:0.005273:0.013064:0.013064:0.011876:0.006532:0.017197:0.005273:0.011924:0.013064:0.013064:0.012447:0.013064:0.011876:0.006532:0.016010:0.013064:0.011876:0.005321:0.013064:0.006603:0.011805:0.006603:0.012993:0.006603:0.006461:0.016010:0.020166:0.013064:0.007720:0.005914:0.011876:0.013064:0.006603:0.006461:0.006603:0.017720:0.005938:0.017197:0.006603:0.012993:0.013064:0.013634:0.013064:0.006603:0.006461:0.013064:0.013064:0.007102:0.006603:0.012993:0.013729:0.008314:0.013064:0.013064:0.007173:0.006603
3.  Diana A, ChristinaO, Catherine C et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing :@0.213836:0.819378:1.835297:0.819378:1.835297:0.800672:0.213836:0.800672:0.013064:0.006532:0.006603:0.016544:0.017197:0.005273:0.013135:0.013064:0.013064:0.008290:0.016010:0.006603:0.008219:0.017197:0.013064:0.007720:0.005273:0.011924:0.006603:0.005273:0.013064:0.013064:0.018979:0.006603:0.008219:0.017197:0.013064:0.006603:0.012993:0.013634:0.007720:0.005273:0.013135:0.013064:0.008290:0.017197:0.008290:0.013064:0.006603:0.008812:0.013064:0.005273:0.006603:0.008290:0.016010:0.013064:0.007720:0.013634:0.013064:0.013064:0.013064:0.013064:0.008884:0.013064:0.013064:0.005273:0.013135:0.013064:0.005273:0.005986:0.013064:0.013064:0.011876:0.008290:0.006603:0.013729:0.007720:0.008884:0.013064:0.019596:0.013064:0.005273:0.007791:0.005273:0.011924:0.013064:0.005273:0.008955:0.013064:0.013064:0.006603:0.005273:0.013064:0.013064:0.012447:0.006603:0.012993:0.007720:0.005273:0.013135:0.005273:0.008361:0.007102:0.013064:0.013064:0.007720:0.013634:0.013064:0.011876:0.008290:0.006603:0.012993:0.007720:0.008884:0.006603:0.012993:0.013064:0.007720:0.005273:0.005392:0.013064:0.008884:0.013064:0.013064:0.013064:0.007102:0.007720:0.013064:0.013634:0.013064:0.013064:0.005273:0.011924:0.008290:0.013064:0.013064:0.006603:0.005273:0.013064:0.013634:0.006603:0.011805:0.008290:0.005273:0.013135:0.008290:0.006603:0.012993:0.013634:0.008290:0.013064:0.007720:0.013064:0.008884:0.013064:0.006603:0.008219:0.013064:0.008290:0.013634:0.016627:0.005273:0.013135:0.013634:0.006603
resistance: summary of the 2011  4  European conference on the infections in Leukaemia.  Haematologica 2013;98(12) :1826-1835 :@0.256580:0.838706:1.648409:0.838706:1.648409:0.820000:0.256580:0.820000:0.007720:0.013064:0.011876:0.005321:0.011876:0.006532:0.013064:0.013064:0.011876:0.013064:0.007102:0.006603:0.011805:0.013064:0.019596:0.020166:0.013064:0.007720:0.011876:0.006532:0.013064:0.007102:0.006603:0.006461:0.013064:0.013064:0.007102:0.013064:0.013064:0.013064:0.013064:0.007102:0.006603:0.013207:0.013135:0.006532:0.016010:0.013064:0.007720:0.013064:0.013634:0.013064:0.013064:0.013064:0.006603:0.011805:0.013634:0.013064:0.006603:0.012993:0.008290:0.013064:0.013064:0.012447:0.013064:0.006603:0.012993:0.013064:0.006603:0.006461:0.013634:0.013064:0.006603:0.005273:0.013064:0.006603:0.012993:0.011876:0.006532:0.005273:0.013705:0.013064:0.011876:0.006532:0.005273:0.013135:0.006603:0.013563:0.013064:0.013064:0.011876:0.013064:0.013634:0.019596:0.005273:0.013135:0.006603:0.006461:0.006603:0.017150:0.013064:0.013634:0.019596:0.013064:0.006603:0.012993:0.005273:0.013705:0.013064:0.005273:0.011924:0.013064:0.006603:0.012993:0.013634:0.013064:0.013064:0.006603:0.013563:0.013064:0.007720:0.013064:0.013064:0.007720:0.007102:0.006603:0.012993:0.013064:0.013634:0.013729:0.007720:0.013064:0.013634:0.013064:0.013682:0.006603
th:@0.627268:0.831600:0.640010:0.831600:0.640010:0.819441:0.627268:0.819441:0.004157:0.008584